GLP-1 Plus by Advanced BioNutritionals enters the spotlight with a patented dihydroberberine (DHB) formula in 2025, reflecting rising interest in GLP-1 alternatives and non-injection hunger support solutions.
GLP-1 Plus by Advanced BioNutritionals enters the spotlight with a patented dihydroberberine (DHB) formula in 2025, reflecting rising interest in GLP-1 alternatives and non-injection hunger support solutions.
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.
FRANKFURT, Germany, Aug. 8, 2025 /PRNewswire/...
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide.
NORTH BERGEN, N.J., Aug. 8, 2025 /PRNewswire/ -- DermaRite Industries, LLC is voluntarily recalling individual lots of products in the table below due to...
AURORA, Ore., Aug. 8, 2025 /PRNewswire/ -- Life Flight Network, the nation's largest not-for-profit air medical transport service has announced the opening of a...
HOLLYWOOD, Fla. and ARLINGTON, Va., Aug. 8, 2025 /PRNewswire/ -- Memorial Healthcare System has launched a comprehensive medication management initiative aimed at enhancing medication...
AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...
Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults
Accelerated approval based on an...
The vitiligo market is witnessing steady growth due to rising disease awareness, improved diagnostic capabilities, and advancements in treatment options such as JAK inhibitors...
NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Breakthrough T1D International, the leading global type 1 diabetes (T1D) research and advocacy organization, in partnership with Friends of...
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF)(the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that it will present at the OTCQB Venture Virtual Investor Conference on August 7th, 2025.